Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM)Susan Bal, Myo Htut, Mehmet H. Kocoglu et al.|Blood|2024Cited by 23
BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy ResultsSusan Bal, Omar Nadeem, Myo Htut et al.|Blood|2024Cited by 6
OA-08 Safety and Preliminary Efficacy of BMS-986393, a GPRC5D CAR T Cell Therapy, in Patients (pts) With Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1–3 Prior Regimens: Results From a Phase 1 StudyMyo Htut, Susan Bal, Omar Nadeem et al.|Clinical Lymphoma Myeloma & Leukemia|2024Cited by 0